CClinicalTrials.gg
Sign In
Not yet recruitingNCT07640776RELIEFUpdated Jun 11, 2026

Irreversible Electroporation (IRE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)

An interventional study of Irreversible Electroporation in Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH), sponsored by Angiodynamics, Inc.. Not yet recruiting. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Angiodynamics, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
50 Years and older
Sex
Male
01

Study summary

This study will evaluate the safety and effectiveness of using Irreversible Electroporation (IRE) for the treatment of symptomatic benign prostatic hyperplasia (BPH).

Read the detailed description

This study will be a prospective, non-randomized study in 40 subjects at up to five clinical sites in the United States. A total of 40 subjects will be treated with IRE and followed for evaluation of primary and secondary endpoints at 6 months post-treatment. Long-term follow-up will continue through 5 years post-treatment for secondary endpoints.

02

Conditions studied

  • Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)

Keywords

  • Lower Urinary Tract Symptoms (LUTS)
  • Benign Prostatic Hyperplasia (BPH)
03

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  1. Male, age ≥50 years.
  2. Clinical diagnosis of symptomatic benign prostatic hyperplasia (BPH).
  3. International Prostate Symptom Score (IPSS) ≥13 at screening.
  4. Peak urinary flow rate (Qmax) ≤12 mL/sec on non-catheterized free flow with voided volume ≥125 mL.
  5. Post-void residual (PVR) ≤250 mL.
  6. Prostate volume between 30 cc and 80 cc by transrectal ultrasound (TRUS) or Magnetic Resonance Imaging (MRI).
  7. Willing and able to comply with all study procedures and follow-up requirements.
  8. Able to provide written informed consent.
  9. Life expectancy ≥10 years.

Exclusion criteria

Exclusion Criteria:

  1. Patients with ≥ Grade Group 2 prostate cancer (≥ Gleason score 7).
  2. Patients with Grade Group 1 prostate cancer (Gleason score 6) on active surveillance for less than 1 year.
  3. Patients with PSA ≥10 ng/mL or PSA density ≥0.15 ng/mL2.
  4. Prior surgical or minimally invasive intervention for BPH (e.g., TURP, Rezūm™, UroLift®, laser therapy).
  5. Presence of urethral stricture or bladder neck contracture.
  6. Patients with a history of pelvic radiation/irradiation.
  7. Patients with compromised renal function (serum creatinine level >1.8 mg/dL or upper-tract disease).
  8. Obstructing median lobe intravesical prostatic protrusion (IPP) with >1 cm assessed by TRUS or MRI.
  9. Active urinary tract infection, prostatitis, or gross hematuria within 3 months of enrollment.
  10. Active need of catheterization.
  11. Known or suspected neurogenic bladder or underlying neurologic disease affecting bladder function (e.g., Parkinson's disease, multiple sclerosis, stroke with residual urinary symptoms).
  12. History of bladder cancer or other urological malignancy.
  13. Implanted electrical devices (e.g., pacemaker, defibrillator, neurostimulator) incompatible with IRE energy delivery.
  14. Uncorrected bleeding diathesis or current therapeutic anticoagulation that cannot be safely interrupted.
  15. Current use of BPH medications unless on a stable dose for ≥6 weeks (alpha-blockers, anticholinergics, beta-3 adrenergic agonists) or ≥6 months (5-alpha reductase inhibitors, phosphodiesterase type 5 inhibitors) prior to baseline, with no planned changes during study follow-up.
  16. Prior rectal or pelvic surgery that may interfere with treatment delivery or evaluation.
  17. Desire to preserve future fertility.
  18. Severe or uncontrolled comorbidities (e.g., NYHA class III/IV heart failure, uncontrolled diabetes, severe pulmonary disease) that, in the opinion of the investigator, would increase study risk or confound outcomes.
  19. Participation in another clinical trial involving an investigational drug or device within 30 days prior to enrollment.
  20. Patients who are members of a vulnerable population, such as the cognitively challenged or incarcerated, that could expose them to undue influence, coercion, or inability to provide informed consent.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Irreversible Electroporation

    Treatment with the NanoKnife System

    Device: Irreversible Electroporation

Interventions

  • DeviceIrreversible Electroporation

    Treatment with the NanoKnife System for ablation of prostate tissue. The procedure will be performed under general anesthesia using transrectal ultrasound (TRUS) guidance. Electrodes will be placed transperineally into predefined treatment zones of the prostate based on imaging and prostate anatomy. Treatment planning will be tailored to target the transition zone bilaterally while preserving key structures, including the neurovascular bundles, external sphincter, and urethra. Electrical pulses will be delivered according to device specifications to achieve focal non-thermal ablation of tissue.

05

What researchers measure

Primary outcomes

  1. Incidence and severity of device-related adverse events (AEs) through 6 months post-procedure

    The primary safety endpoint is the incidence and severity of device-related adverse events (AEs) through 6 months post-procedure, categorized using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: From treatment through 6 months post-procedure

  2. Mean change in International Prostate Symptom Score (IPSS) from baseline to 6 months post-procedure

    The primary effectiveness endpoint is the mean change in International Prostate Symptom Score (IPSS) from baseline to 6 months post-procedure, assessing improvement in lower urinary tract symptoms attributable to benign prostatic hyperplasia (BPH)

    Time frame: From baseline through 6 months post-procedure

Secondary outcomes

  1. Technical success

    The technical success of the procedure, defined to be successful energy delivery per the treating physician

    Time frame: Immediately after the procedure

  2. Incidence and severity of device-related adverse events (AEs) through 12 months post-procedure

    The incidence and severity of device-related adverse events (AEs) through 12 months post-procedure, categorized using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: From treatment through 12 months post-procedure

  3. Incidence, relatedness, seriousness, and severity of all adverse events (AEs) through 6 months post-procedure

    The incidence, relatedness, seriousness, and severity of all adverse events (AEs) through 6 months post-procedure, categorized using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: From treatment through 6 months post-procedure

  4. Incidence, relatedness, seriousness, and severity of all adverse events (AEs) through 12 months post-procedure

    The incidence, relatedness, seriousness, and severity of all adverse events (AEs) through 12 months post-procedure, categorized using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: From treatment through 12 months post-procedure

  5. Rate of ablations that were completed successfully per the treating physician

    Rate of ablations that were completed successfully per the treating physician

    Time frame: Immediately after the procedure

  6. Change in IPSS from baseline to 1, 3, 12, 24, 36, 48 and 60 months post-procedure

    Change in IPSS from baseline to 1, 3, 12, 24, 36, 48 and 60 months post-procedure, assessing durability of symptom improvement over time

    Time frame: From baseline to 1, 3, 12, 24, 36, 48 and 60 months post-procedure

  7. Change in IPSS Quality of Life (IPSS-QoL) score from baseline to 1, 3, 6, 12, 24, 36, 48 and 60 months

    Change in IPSS Quality of Life (IPSS-QoL) score from baseline to 1, 3, 6, 12, 24, 36, 48 and 60 months

    Time frame: From baseline to 1, 3, 6, 12, 24, 36, 48 and 60 months

  8. Change in maximum urinary flow rate (Qmax) from baseline to 1, 3, 6, 12, 24, 36, 48 and 60 months

    Change in maximum urinary flow rate (Qmax) from baseline to 1, 3, 6, 12, 24, 36, 48 and 60 months, measured by non-invasive uroflowmetry.

    Time frame: From baseline to 1, 3, 6, 12, 24, 36, 48 and 60 months

  9. Change in post-void residual (PVR) urine volume from baseline to 1, 3, 6, 12, 24, 36, 48 and 60 months

    Change in post-void residual (PVR) urine volume from baseline to 1, 3, 6, 12, 24, 36, 48 and 60 months

    Time frame: From baseline to 1, 3, 6, 12, 24, 36, 48 and 60 months.

  10. Change in prostate volume from baseline to 6, 12, 24, 36, 48 and 60 months

    Change in prostate volume as assessed by transrectal ultrasound (TRUS) or MRI from baseline to 6, 12, 24, 36, 48 and 60 months

    Time frame: From baseline to 6, 12, 24, 36, 48 and 60 months

  11. Incidence of unplanned BPH-related interventions within 12 months following the procedure

    Incidence of unplanned BPH-related interventions (e.g., catheterization, medication initiation, surgery) within 12 months following the procedure

    Time frame: From treatment through 12 months post-procedure

  12. Change in sexual function as measured by the International Index of Erectile Function (IIEF-5) at baseline and 1, 3, 6, 12, 24, 36, 48 and 60 months

    Change in sexual function as measured by the International Index of Erectile Function (IIEF-5) at baseline and 1, 3, 6, 12, 24, 36, 48 and 60 months

    Time frame: From baseline and 1, 3, 6, 12, 24, 36, 48 and 60 months

  13. Change in ejaculatory dysfunction as measured by the Male Sexual Health Questionnaire - Ejaculation Short Form (MSHQ-EjD-SF) at baseline and 1, 3, 6, 12, 24, 36, 48 and 60 months

    Change in ejaculatory dysfunction as measured by the Male Sexual Health Questionnaire - Ejaculation Short Form (MSHQ-EjD-SF) at baseline and 1, 3, 6, 12, 24, 36, 48 and 60 months

    Time frame: From baseline and 1, 3, 6, 12, 24, 36, 48 and 60 months

  14. Change in health-related quality of life (HRQoL) as measured by the EQ-5D-5L and EQ VAS instrument from baseline to 6, 12, 24, 36, 48 and 60 months

    Change in health-related quality of life (HRQoL) as measured by the EQ-5D-5L and EQ VAS instrument from baseline to 6, 12, 24, 36, 48 and 60 months

    Time frame: From baseline to 6, 12, 24, 36, 48 and 60 months

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT07640776
Lead sponsor
Angiodynamics, Inc.
Responsible party
Sponsor
First posted
Jun 11, 2026
Start date
Sep 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Jun 2031 (estimated)
Last update
Jun 11, 2026

Study contacts

Elizabeth Manning Sr. Director, Clinical Affairs
Contact
liz.manning@angiodynamics.com
339-237-2765

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lower Urinary Tract Symptoms→

Other studies from this sponsor

Angiodynamics, Inc.

Start the discussion